Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study

Annals of Oncology : Official Journal of the European Society for Medical Oncology
D A RichardsK D Dasse

Abstract

CI-994, an oral histone deacetylase inhibitor, has antineoplastic activity and synergism with gemcitabine preclinically. This randomized phase II trial explored whether CI-994 plus gemcitabine improves overall survival, objective response, duration of response, time to treatment failure and change in quality of life (QoL) or pain compared with gemcitabine alone. A total of 174 patients received CG (CI-994 6 mg/m(2)/day days 1-21 plus gemcitabine 1000 mg/m(2) days 1, 8 and 15 each 28-day cycle) or PG (placebo plus gemcitabine 1000 mg/m(2) days 1, 8 and 15 of each 28-day cycle days 1-21). Median survival was 194 days (CG) versus 214 days (PG) (P = 0.908). The objective response rate with CG was 12% versus 14% with PG when investigator-assessed and 1% versus 6%, respectively, when assessed centrally. Time to treatment failure did not differ between the two arms (P = 0.304). QoL scores at 2 months were worse with CG than with PG. Pain response rates were similar between the two groups. There was an increased incidence of neutropenia and thrombocytopenia with CG. Adding CI-994 to gemcitabine in advanced pancreatic carcinoma does not improve overall survival, response rate or time to progression; CG produced decreased QoL and increas...Continue Reading

References

Aug 1, 1996·Cancer·J D Ahlgren
Jan 1, 1996·Investigational New Drugs·B J FosterL H Baker
Jun 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H A BurrisD D Von Hoff
Sep 5, 1998·Cancer Treatment Reviews·C KollmannsbergerU Fink
Oct 26, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·D FitzsimmonsT Tihanyi
Aug 3, 2000·Journal of the National Cancer Institute·P A MarksR A Rifkind
Apr 9, 2001·Investigational New Drugs·S PrakashP M LoRusso
Aug 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jordan D BerlinAl Bowen Benson
Aug 22, 2002·Proceedings of the National Academy of Sciences of the United States of America·Lisa M ButlerVictoria M Richon
Jul 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Margaret TemperoJames Abbruzzese
Aug 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J MooreUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Feb 21, 2004·CA: a Cancer Journal for Clinicians·Ahmedin JemalUNKNOWN American Cancer Society
Apr 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E Van CutsemD Von Hoff
Aug 26, 2004·Advances in Cancer Research·Paul A MarksWilliam Kevin Kelly
Sep 15, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Caio M Rocha LimaLangdon L Miller
May 24, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C LouvetUNKNOWN GISCAD
Aug 10, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H OettleH L Kindler
Apr 26, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mark J RatainPeter J O'Dwyer

❮ Previous
Next ❯

Citations

Sep 22, 2007·Annual Review of Pharmacology and Toxicology·Carolyn Ptak, Arturas Petronis
Mar 1, 2010·Therapeutic Advances in Medical Oncology·Ben Lawrence, Michael Findlay
Jun 1, 2011·Cancer Management and Research·Nadine Martinet, Philippe Bertrand
Jul 3, 2008·World Journal of Gastroenterology : WJG·Martin HaefnerMarcus Wiedmann
Sep 25, 2012·World Journal of Gastroenterology : WJG·Chen SunDe-Quan Wu
Mar 14, 2013·World Journal of Gastroenterology : WJG·Ioannis KoutsounasStamatios Theocharis
Mar 28, 2008·Expert Review of Anticancer Therapy·Walid RasheedH Miles Prince
Apr 28, 2007·Expert Opinion on Investigational Drugs·Walid K RasheedH Miles Prince
Jan 29, 2016·Critical Reviews in Oncology/hematology·A KristensenT S Solheim
Mar 20, 2012·Cancer Letters·Sau Wai HungRajgopal Govindarajan
Mar 26, 2011·Clinics and Research in Hepatology and Gastroenterology·Isabelle TrouilloudJulien Taieb
Oct 1, 2015·The Journal of Pathology·Chang-Il HwangDavid A Tuveson
Nov 17, 2009·Surgical Oncology Clinics of North America·Udo RudloffPeter J Allen
Dec 23, 2015·Clinical Epigenetics·Clara NerviGiovanni Codacci-Pisanelli
Nov 26, 2009·Journal of Cellular and Molecular Medicine·Günter SchneiderDieter Saur
May 25, 2012·Expert Opinion on Therapeutic Targets·Syed F ZafarBassel El-Rayes
Jun 28, 2013·Epigenetics : Official Journal of the DNA Methylation Society·Yajie WangJacob Hooker
Apr 20, 2010·Molecular Cancer·Susanne SchülerGünter Schneider
Jul 28, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Tsuyoshi HamadaKazuhiko Koike
Sep 27, 2016·Expert Opinion on Investigational Drugs·Alexander Arlt, Heiner Schäfer
Sep 7, 2005·Seminars in Oncology·Howard A Burris
Jun 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Asma SultanaPaula Ghaneh
Aug 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jürg BernhardUNKNOWN Central European Cooperative Oncology Group
Jul 18, 2006·Molecular & Cellular Proteomics : MCP·Karl E Krueger, Sudhir Srivastava
Jan 30, 2009·Journal of Cellular and Molecular Medicine·M W LawlessS G Gray
Nov 28, 2007·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Kathy L Kopnisky, Jing Bao
Jul 10, 2009·The Cochrane Database of Systematic Reviews·Julia BohliusAndreas Engert
Dec 14, 2012·The Cochrane Database of Systematic Reviews·Thomy ToniaJulia Bohlius
Oct 2, 2013·Indian Journal of Endocrinology and Metabolism·Ambika Gopalakrishnan UnnikrishnanPaturi V Rao
Jul 1, 2020·International Journal of Cancer. Journal International Du Cancer·Xin ZhangJens T Siveke

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
S D UndeviaM J Ratain
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
V HeinemannRalf Wilkowski
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Malcolm J MooreNational Cancer Institute of Canada Clinical Trials Group
© 2022 Meta ULC. All rights reserved